Dragonfly Opstar
Payments companies reported to CMS as associated with Dragonfly Opstar. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Dragonfly Opstar, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Dragonfly Opstar
These are the largest totals companies reported as associated with Dragonfly Opstar. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hayder Hashim | Washington, DC | Cardiovascular Disease | $48,671.13 |
| Darshan Doshi | Boston, MA | Interventional Cardiology | $46,267.97 |
| Sripal Bangalore | New York, NY | Interventional Cardiology | $30,632.47 |
| Ryan Madder | Royal Oak, MI | Interventional Cardiology | $29,606.20 |
| Daniel Kiss | Eatontown, NJ | Interventional Cardiology | $20,868.00 |
| Richard Sohn | Portland, OR | Interventional Cardiology | $20,803.08 |
| Vamsi Krishna | Kyle, TX | Interventional Cardiology | $20,526.14 |
| Jeffrey Southard | Sacramento, CA | Cardiovascular Disease | $14,016.64 |
| Brock Cookman | Lincoln, NE | Interventional Cardiology | $13,103.45 |
| Mohamadamer Alaiti | Plano, TX | Interventional Cardiology | $13,093.35 |
Prescribed Dragonfly Opstar?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.